

DAFTAR PUSTAKA

- Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. *Gastroenterol Hepatol (N Y)*. 2012;8:605-7.
- Afdhal NH, Bacon BR, Patel K, et al. Accuracy of Fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study [published online December 18][2014] *Clin Gastroenterol Hepatol*. doi:10.1016/j.cgh.2014.12.014. [PubMed]
- Alter MJ: Epidemiology of hepatitis C virus infection. *World J Gastroenterol* 2007, 13(17):2436-41 Butt AA: Hepatitis C virus infection: the new global epidemic. *Expert Rev Anti Infect Ther* 2005, 3:241-9.
- Arber N, Konikoff FM, Moshkowitz M, Baratz M, Hallak A, Santo M. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. *Chinese Medical Journal* 5 April 2017 5 Volume 130 5 Issue 7 871 et al. *Dig Dis Sci* 1994;39:2656-9. doi: 10.1007/bf02087705.
- Arezes J, Nemeth E. Hcpidin and iron disorders: new biology and clinical approaches. *Int J Lab Hematol*. 2015 May;37 Suppl 1:92-8.
- Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muyenck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P: Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. *Liver Int* 2010, ISSN 1478-3223.
- Barbaro G, Di Lorenzo G, Asti A, Ribersani M, Belloni G, Grisorio B, Filice G, Barbarini G: Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. *Am J Gastroenterol* 1999, 94(8):2198–2205
- Bartenschlager R, Lohmann V. 2000. Replication of Hepatitis C Virus. *Journal of Virology*. 81(7): 1631-48
- Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasif. *Hepatology*. 2012;55:58-67.
- Brissot, P., Bourel, M., Herry, D. *et al.* (1981) Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. *Gastroenterology*; 80, pp. 557–565

- Butt AS. Epidemiology of Viral Hepatitis and Liver Diseases in Pakistan. *Euroasian J Hepato-Gastroenterol* 2015;5(1):43-48.
- Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology*. 2010;128:343-50.
- Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. *Gastroenterology*. 2012;142:1293-1302.e4.
- Chaudhry R, Babiker HM. (2019) Physiology, Coagulation Pathways. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482253/>.
- Chayama K, Hayes CN. Hepatitis C virus: How genetic variability affects pathobiology of disease. *J Gastroenterol Hepatol*. 2011;26 Suppl 1:83-95.
- Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. *Int J Med Sci*. 2006;3:47-52.
- Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 2010, 244(4902):359-362.
- Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. *Ann Intern Med*. 2013;158:807-20.
- Cohen-Solal A, Leclercq C, Deray G, Lasocki S, Zambrowski JJ, Mebazaa A, de Groote P, Damy T, Galinier M. Iron deficiency: an emerging therapeutic target in heart failure. *Heart*. 2014 Sep 15;100(18):1414-20.
- Demirtürk N, Demirdal T, Toprak D, Altindiş M, Aktepe OC: Hepatitis B and C virus in West-Central Turkey: Seroprevalence in healthy individuals admitted to a university hospital for routine health checks. *Turk J Gastroenterol* 2006, 17:267-72.
- Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. *Gastroenterology* 1992;102:2108-13. doi: 10.1016/0016-5085(92) 90339-Z. *essentials. WMJ*. 2015;114(6):263-269.

- Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. 2017. Panduan Singkat Tatalaksana Hepatitis C. Jakarta: Kementerian Kesehatan Republik Indonesia.
- El Lehleh AM, El Shazly RA, Hamza RR. Study of serum hepcidin in patients with chronic hepatitis C. *Menoufia Med J* 2017;30:721-6
- European Association for The Study of The Liver (EASL). 2018. Recommendations on Treatment of Hepatitis. *Journal of Hepatology*.
- European Association for The Study of The Liver (EASL). 2014. Clinical Practice Guidelines: Management of Hepatitis C Virus Infection. *Journal of Hepatology*.67: 370-398
- Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R: Iron storage, lipid peroxidation and glutathione turnover in chronic anti-VHC positive hepatitis. *J Hepatol* 1995, 22(4):449–456.
- Forns X, Purcell RH, Bukh J: Quasispecies in viral persistence and pathogenesis of hepatitis C virus. *Trends Microbiol* 1999, 7(10):402–410
- Friedman SL. Evolving challenges in hepatic fibrosis. *Nat Rev Gastroenterol Hepatol*. 2010;7:425-36.
- Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. *Mol Med*. 2007;13:97-104.
- Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. *J Hepatol*. 2008;49:702-10
- Gani RA, Hasan I, Sanitiyoso A, Lesmana CR, Wasposito A & Siregar L. 2014. Konsensus Nasional Penatalaksanaan Hepatitis C di Indonesia. Perhimpunan Peneliti Hati Indonesia (PPHI): 13-19
- Ganz, T., Olbina, G., Girelli, D., Nemeth, E., Westerman, M. (2008).Immunoassay for human serum hepcidin.*Blood*, 112, pp. 4292–4297.

- Ganz T. Heparin and iron regulation, 10 years later. *Blood*. 2011;117:4425-33.
- García-Monzón C, Majano PL, Zubia I, Sanz P, Apolinario A, Moreno-Otero R: Intrahepatic accumulation of nitrotyrosine in chronic viral hepatitis is associated with histological severity of liver disease. *J Hepatol* 2000, 32(2):331–338.
- Gardenghi S, Grady RW, Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β -thalassemia. *Hematol Oncol Clin North Am*. 2010;24:1089-107.
- Girelli D, pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, et al. 2009. Reduce serum hepcidin level in patient with chronic hepatitis C. *J Hepatol*;51:845-42
- Goldberg E, Chopra, S. Cirrhosis in adults. UpToDate. 2016. www.uptodate.com
- Gower E, Estes C, Blach C, Rasavi H. 2014. Global Epidemiology and Genotype Distribution of Hepatitis C Virus Infection. *Journal of Hepatology*. 51:S45-57.
- Haklar, G. (2016) Liver function tests in chronic viral hepatitis cases. *Marmara Medical Journal*, 29, pp. 6-9, doi: 10.5472/MMJsi.2901.03.
- Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology* 2013; 57:1333.
- Harris HE, Ramsay ME, Andrews N, Eldridge KP: Clinical course of hepatitis C virus during the first decade of infection: cohort study. *BMJ* 2002, 324:1-6.
- Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. *Annu Rev Pathol*. 2011;6:425-56
- Hézode C, Cazeneuve C, Coué O, Roudot-Thoraval F, Lonjon I, Bastie A, et al. Liver iron accumulation in patients with chronic active hepatitis C: Prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. *J Hepatol* 1999;31:979-84. doi: 10.1016/s0168-8278(99)80308-0.

- Hino K, Nishina S, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. *Gastroenterology* 2013 , vol. 134 (pg. 226-238)
- Hörl WH, Schmidt A. Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C. *Nephrol Dial Transplant* (2014) 29: 1141-1144.
- Isom HC, McDevitt EI, Moon MS. Elevated hepatic iron: A confounding factor in chronic hepatitis C. *Biochim Biophys Acta* 2009;1790:65062. doi: 10.1016/j.bbagen.2009.04.009.
- Ivanov AV, Bartosch B, Smirnova OA, Isaguliantz MG, Kochetkov SN: VHC and Oxidative Stress in the Liver. *Viruses* 2013, 5(2):439–469.
- Jawaid A, Khuwaja AK: Treatment and vaccination for hepatitis C: present and future. *J Ayub Med Coll Abbottabad* 2008, 20(1):129-33.
- Kemna EH, Kartikasari AE, van Tits LJ, Pickkers P, Tjalsma H, Swinkels DW. Regulation of hepcidin: insights from biochemical analyses on human serum samples. *Blood Cells Mol Dis.* 2008 May-Jun;40(3):339-46. Epub 2007 Nov 26.
- Khusun, H., Yip, R., Schultink, W., Dillon, D.H. (1999). World Health Organization hemoglobin cut-off points for the detection of anemia are valid for an Indonesian population. *J Nutr.*, 129(9), pp. 1669-1674.
- Kilany, Y.F., Elghanam, M.K., Hammad, K.S. (2015). Study of some hematological and haemostasis aspects in Chronic C Virus. *Al-Azhar Assiut Medical Journal*, 13(2), pp. 118-124.
- Koda, M., Matunaga, Y., Kawakami, M., Kishimoto, Y., Suou, T., Murawaki, Y. (2007) FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. *Hepatology*, 45, pp. 297–306.
- Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. *World J Gastroenterol* 2007; 13(35): 4699-4706
- Koliaraki, V. *et al.* (2008). Iron regulatory and bactericidal properties of human recombinant hepcidin expressed in *Pichia pastoris*. *Biochimie*, 90, pp. 726–735.
- Koliaraki, V. *et al.* (2009). A novel immunological assay for hepcidin quantification in human serum. *PLoS ONE*, 4: e4581.

- Kulaksiz, H., Gehrke, S.G., Janetzko, A., et al. (2004) Pro-hepcidin: Expression and cell specific localization in the liver and its regulation in hereditaryhaemochromatosis, chronic renal insufficiency, and renal anaemia. *Gut*,2(53), pp. 735–743.
- Lee J, Conniff J, Kraus C, Schragar S. A brief clinical update on hepatitis C—the essentials. *WMJ*. 2015 Dec;114(6):263-9; quiz 270.
- Lin D, Ding J, Liu J-Y, He Y-F, Dai Z, Chen C-Z, et al. Decreased serum Hepcidin concentration correlates with brain iron deposition in patients with HCV related cirrhosis. *PLoS One*. 2013;8:e65551
- Lu S, Bennett RG, Kharbanda KK, Harrison-Findik DD. Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. *World J Hepatol*. 2016;8:211-25.
- Lu S, Natarajan SK, Mott JL, Kharbanda KK, Harrison-Findik DD. Ceramide induces human Hepcidin gene transcription through JAK/STAT3 pathway. *PLoS One*. 2016;11:e0147474.
- Marcellin P, Asselah T & Boyer N. 2002. Fibrosis and Disease Progression in Hepatitis C. *hepatology*. Vol. 3 No. 5 Suppl.1: S47-56
- Mastroianni CM, Lichtner M, Mascia C, Zuccala P & Vulo V. 2014. Molecular Mechanism of Liver Fibrosis in HIV/HCV Coinfection. *International Journal of Moulecular Sciences*, Vol. 61, NO. 1:77-78
- Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. *Am J Gastroenterol* 2004;99:286-91. doi: 10.1111/j.1572-0241.2004.04049.x
- Milic S, Mikolasevic I, Orlic L, Devcic E, Starcevic, Cizmarevic N, Stimac D, et al. The role of iron and iron overload in chronic liver disease. *Med Sci Monit* 2016;22:214451. doi: 10.12659/msm.896494.
- Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. *Hepatology*. 2008;48:1420-9.
- Muriel P: Role of free radicals in liver diseases. *Hepatol Int* 2009, 3(4):526–536.
- Pinzani M. Pathophysiology of Liver Fibrosis. *Dig Dis*. 2015;33:492-7.

- Nadeem, A., Hussai, M.M., Aslam, M. (2010) Correlation of serum alanine aminotransferase and aspartateaminotransferaselevels to liver histology in chronic hepatitis C. *Journal of the College of Physicians and Surgeons Pakistan*, 20(10), pp. 657-661.
- Nagashima M, Kudo M, Chung H, Ishikawa E, Hagiwara S, Nakatani T, et al. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. *Hepatol Res*. 2006;36:288-93.
- Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. *Proc Natl Acad Sci*. 2001;98:8780-5.
- Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. *Gastroenterology*. 2008 Jan;134(1):226-38.
- Olmez, O.F., Gurel, S. danYilmaz, Y. (2010) Plasma prohepcidin levels in patients with chronic viral hepatitis : Relationship with liver fibrosis, *European Journal of Gastroenterology and Hepatology*, 22(4), pp. 461-465.
- Osterholm, E.A., Georgieff, M.K. (2015) Chronic Inflammation and Iron Metabolism. *J Pediatr*, 166(6), pp. 1351–1357.
- Paracha UZ, Fatima K, Alqahtani M, Chaudhary A, Abuzenadah A, Damanhoury G, Qadri I. Oxidative stress and hepatitis C virus. *Virol J*. 2013 Aug 7;10:251.
- Price L, Kowdley KV. The role of iron in the pathophysiology and treatment of chronic hepatitis C. *Can J Gastroenterol* 2009;23:8228. doi: 10.1155/2009/290383.
- Rau M, Baur K, Geier A. Host genetic variants in the pathogenesis of hepatitis C. *Viruses*. 2012;4:3281–3302.2007.
- Riset Kesehatan Dasar (Riskesdas). Laporan Nasional 2007. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia.

- Riset Kesehatan Dasar (Riskesdas). Laporan Nasional 2013. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. *Hepatology*. 2009;49:1017-44.
- Rosen HR, Gretch DR: Hepatitis C virus: current understanding and prospects for future therapies. *Mol Med Today* 1999, 5(9):393–399.
- Rosen HR. Clinical practice. Chronic hepatitis C infection. *N Engl J Med*. 2011;364(25):2429-2438.
- Sarin SK, Kumar M. Natural history of VHC infection. *Hepatol Int*. 2012; 6(4):684-695.
- Seki E, Brenner DA. Recent advancement of molecular mechanisms of liver fibrosis. *J Hepatobiliary Pancreat Sci*. 2015;22:512-8.
- Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. *World J Gastroenterol*. 2014;20:16820-30.
- Shiha G, Sarin S, Ibrahim A, Omata M, Kumar A & Lesmana L. 2009. Liver Fibrosis: consensus recommendations of the Asian Pacific Association for the Study of The Liver (APASL). *Hepatology International*; 3(2): 323-333
- Sievert W, Altarif I, Razavi HA, Abdo A, Ahmed EA, OAmir AA, Amarpurkar D & Chen CH. 2011. A systemic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. *Liver International*: 61-80
- Simmonds P: Genetic diversity and evolution of hepatitis C virus-15 years on. *J Gen Virol* 2004, 85(Pt11):3173–3188.
- Soriano V, Peters GM, Marion, Zeuzem S: New Therapies for Hepatitis C Virus Infection. *Clinical Infectious Diseases* 2009, 48:313-20.
- Steadman R, Myers RP, Leggett L, et al. A health technology assessment of transient elastography in adult liver disease. *Can J Gastroenterol*. 2013;27:149-58.

- Sugimoto, R. *et al.* (2009). Impaired regulation of serum hepcidin during phlebotomy in patients with chronic hepatitis C. *Hepatology Research*, 39, pp. 619-624.
- Sulaiman A. 2017. Konsensus Nasional Penatalaksanaan Hepatitis C di Indonesia. Perhimpunan Peneliti Hati Indonesia (PHPI).
- Taher AT, Musallam KM, Inati A. Iron overload: Consequences, assessment, and monitoring. *Hemoglobin* 2009;33 Suppl 1:S4657. doi: 10.3109/03630260903346676.
- Tawfik NM, Hegazy MA, Maksoud IAA, Nasr AS. Iron Load and Serum Hepcidin in Hepatitis C Virus Related Hepatocellular Carcinoma. *Euroasian J Hepato Gastroenterol*. 2012;2(1):24-27.
- Terrence CH, Darreell HG, Michael E et al. The serum hepcidin: ferritin ratio is a potential biomarker for cirrhosis. *Liver International*. 2012: 32(9):1391-1399.
- Trickey, A. *et al.* (2017) Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan, *American Journal of Tropical Medicine and Hygiene*, 97(6), pp. 1920-1928.
- Tsai, M. *et al.* (2015) Predictors for early identification of hepatitis C virus infection. *BioMed Research International*, 2015, pp. 1-7.
- Tsochatzis E, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G, Manesis EK, et al. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. *J Viral Hepat*. 2010;17:800–6.
- Vela D. Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker. *Molecular Medicine*. 2018;24:5.
- Verga FMV, Vujic SM, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. *Blood*. 2007 Jan 1;109(1):353-8. Epub 2006 Aug 31.
- Wang Y. Scotomas in molecular virology and epidemiology of hepatitis C virus. *World J Gastroenterol*. 2013;19:7910–7921.
- Wallace DF. The Regulation of Iron Absorption and Homeostasis. *Clin Biochem Rev*. 2016 May; 37(2): 51–62.
- Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. *Blood*. 2006;108:3204-9.

World Health Organization. 2016. Global Report on Acces to Hepatitis C Treatment: Focus on Overcoming Barriers. Geneva

Zeuzem, S. *et al.* (2006) Review article: management of patients with chronic hepatitis C virus infection and “normal” alanine aminotransferase activity. *Aliment PharmacolTher.*, 2, pp. 1133–49.

Zou Dm, Sun WL. 2017. Relationship between Hepatitis C Virus Infection and Iron Overload. *Chin Med J*, 130:866-71